Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics

Watanabe, Hirofumi; Nagano, Nobuhiko; Tsuji, Yasuhiro; Noto, Nobutaka; Ayusawa, Mamoru; Morioka, Ichiro

doi:10.1007/s00228-023-03598-x

Cited by 3 publications

(1 citation statement)

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…research results have played an important role in designing new drugs; optimizing drug administration schedules; improving drug dosage forms; and providing efficient, rapid, long-lasting, low-toxicity, and tolerable drugs with effects (Wang et al, 2024;Watanabe et al, 2024). For drug pharmacokinetic analysis, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) is faster and provides a number of benefits over high-performance liquid chromatography-UV and liquid chromatography-tandem mass spectrometry (Chen et al, 2024;Huang et al, 2022;Lin et al, 2022;Yu et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of IMM‐H012 in rats using ultra‐performance liquid chromatography‐tandem mass spectrometry

Wu,

Lin

et al. 2024

Biomedical Chromatography

View full text Add to dashboard Cite

The present study examined the pharmacokinetics of IMM‐H012 in rat plasma, utilizing ultra‐performance liquid chromatography‐tandem mass spectrometry (UPLC‐MS/MS). Internal standard cilostazol was employed, and plasma samples were processed using acetonitrile precipitation. A mobile phase (acetonitrile–0.1% formic acid in water) with gradient elution was used to achieve chromatographic separation using a UPLC BEH C18 column. In multiple reaction monitoring mode, electrospray ionization MS/MS was utilized in positive ionization mode. Based on findings, the lower limit of quantification was 2 ng/mL, and the linearity of IMM‐H012 in rat plasma was found to be acceptable within the range of 2–2000 ng/mL (R2 > 0.995). The intra‐day and inter‐day precision relative standard deviation was less than 14% of IMM‐H012 in rat plasma. The matrix effect was within the range of 102%–107%, and the accuracy ranged from 92% to 113%. Pharmacokinetics of IMM‐H012 in rats after oral administration were successfully studied using UPLC‐MS/MS.

show abstract